Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study

The Lancet. Haematology
Walter AgenoAlexander G G Turpie

Abstract

The efficacy and safety of the anticoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been shown in phase 3 trials. However, data about rivaroxaban use in routine clinical practice are needed. XA inhibition with rivaroxaban for Long-term and Initial Anticoagulation in venous thromboembolism (XALIA) was a multicentre, international, prospective, non-interventional study of patients with deep-vein thrombosis, done in hospitals and community care centres in 21 countries. The study investigated the safety and effectiveness of rivaroxaban compared with standard anticoagulation therapy (initial treatment with unfractionated heparin, low-molecular-weight heparin, or fondaparinux, usually overlapping with and followed by a vitamin K antagonist) for at least 3 months. Eligible patients were adults (aged ≥18 years) with an objectively confirmed diagnosis of deep-vein thrombosis, and an indication to receive anticoagulation treatment for at least 3 months. Following approval of rivaroxaban for the pulmonary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism were also eligible; however, those with isolated pulmonary embolism were not in...Continue Reading

References

Nov 8, 2008·Thrombosis and Haemostasis·José Antonio NietoUNKNOWN RIETE Investigators
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Jan 26, 2011·Statistical Methods in Medical Research·Elizabeth WilliamsonJames Carpenter
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
Sep 11, 2012·Best Practice & Research. Clinical Haematology·Samuel Z Goldhaber
Dec 12, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY-EXT Investigators
Feb 22, 2013·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-SONATE Trial Investigators
Jul 3, 2013·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY Investigators
Sep 3, 2013·The New England Journal of Medicine·Harry R BüllerPhil Wells
Dec 18, 2013·Circulation·Sam SchulmanUNKNOWN RE-COVER II Trial Investigators

❮ Previous
Next ❯

Citations

Apr 12, 2016·The Lancet. Haematology·Dominique StephanSébastien Gaertner
Apr 12, 2016·The Lancet. Haematology·Walter AgenoAlexander G G Turpie
Jun 4, 2016·Drugs & Aging·Jir Ping Boey, Alexander Gallus
Sep 15, 2016·Thrombosis and Haemostasis·Jan Beyer-WestendorfSally Tamayo
Sep 15, 2016·Thrombosis and Haemostasis·Walter Ageno, Alexander G G Turpie
Sep 23, 2016·Thrombosis and Haemostasis·Jeffrey I WeitzAjay K Kakkar
Sep 27, 2016·Expert Opinion on Pharmacotherapy·Christos VoukalisEduard Shantsila
Oct 4, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Emanuel RaschiFabrizio De Ponti
Oct 4, 2016·Archives of Cardiovascular Diseases·Dominique StephanSébastien Gaertner
Jul 5, 2016·Lancet·Marcello Di NisioHarry R Büller
Dec 6, 2016·Expert Opinion on Pharmacotherapy·Bobby GouinMarc Blondon
Apr 21, 2017·Thrombosis and Haemostasis·Sam SchulmanSamuel Z Goldhaber
May 12, 2016·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Caio Julio Cesar Dos Santos FernandesRogerio Souza
Mar 21, 2017·Journal of Thrombosis and Haemostasis : JTH·J-P GalanaudJ-L Bosson
Jul 6, 2017·Journal of Clinical Pharmacology·Liping ZhangKenneth Todd Moore
Apr 20, 2016·Therapeutic Advances in Cardiovascular Disease·James Uprichard
Mar 16, 2018·Expert Review of Respiratory Medicine·Luke S Howard
Sep 16, 2017·Journal of Thrombosis and Thrombolysis·Michela GiustozziCecilia Becattini
Aug 6, 2017·Internal and Emergency Medicine·Francesco DentaliMonica Gianni
Oct 4, 2018·BMJ Evidence-based Medicine·Mukul BhattaraiYoussef Chami
Sep 2, 2016·European Respiratory Review : an Official Journal of the European Respiratory Society·Massimo Franchini, Pier Mannuccio Mannucci
Mar 29, 2019·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Alexander T Cohen, Rupert Bauersachs
Dec 7, 2018·Hematology·Walter Ageno, Marco Donadini
Jul 14, 2019·Journal of Thrombosis and Haemostasis : JTH·Noémie KraaijpoelGrégoire Le Gal
Dec 1, 2019·Journal of Thrombosis and Haemostasis : JTH·Yuji NishimotoUNKNOWN COMMAND VTE Registry Group
Jan 15, 2020·Circulation Journal : Official Journal of the Japanese Circulation Society·Cheng-Han LeeYi-Heng Li
Jan 12, 2020·Journal of Thrombosis and Haemostasis : JTH·Marc BlondonHelia Robert-Ebadi
Jun 9, 2020·Journal of Thrombosis and Haemostasis : JTH·Victoria SpeedJignesh P Patel
Feb 18, 2017·Journal of Gastroenterology·Sven PannachJan Beyer-Westendorf
Jul 26, 2017·Expert Review of Hematology·Alexandra Sophie MossGregory Y H Lip

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.